Immunotherapy, Vaccines and Virotherapy
Improving a virus’ cancer-killing potency
In recent years, an unusual new domain in cancer research has opened up. The idea is to use infectious pathogens to attack and kill cancerous cells. So-called oncolytic viruses, in particular, have shown great promise for targeting cancer cells, while leaving normal, healthy cells intact.
Arizona Town Hall Meeting on COVID-19 Vaccine Safety
Scientists at Arizona State University and University of Arizona have joined a national effort to educate the general public about COVID-19 vaccination. Leading Arizona's discussions will be: Felicia Goodrum, PhD, University of Arizona College of Medicine James Alwine, PhD, University of Arizona Grant McFadden, PhD, director, Biodesign Center for Immunotherapy, Vaccines and Virotherapy Brenda Hogue, PhD, Biodesign Center for Immunotherapy, Vaccines and...
A dose of facts: Answering your COVID-19 vaccine questions
Over 170 million people in the U.S. are now fully vaccinated against COVID-19 -- more than half of the country's population. But as the virus evolves and new variants emerge,
Introduction to the molecular biology of COVID-19 vaccines and vaccine candidates
Ian Hogue, PhD Biodesign Center for Immunotherapy, Vaccines and Virotherapy presents: Introduction to the molecular biology of COVID-19 vaccines and vaccine candidates This is part of the Navajo Emerging Infection and Tribal Communities Conference on Emerging Infection and Tribal Communities. Registration is free. Register
Arizona Wellbeing Commons finds answers for COVID-19, hope for future
After battling on the front lines of the global coronavirus pandemic for nearly a year, Arizona’s health care community paused last Friday to evaluate what we’ve learned about COVID-19, what
Undaunted: ASU Science forges ahead, despite worldwide crisis
The global pandemic caused by the novel coronavirus has affected nearly every aspect of daily life in Arizona and across the nation, putting many summer activities on pause in the
An unconventional solution: Researchers recognized by ASU Women and Philanthropy for salmonella-based cancer therapy
Standard-of-care treatments—chemotherapy and radiation—remain at the forefront of cancer therapy, but in light of the high rate of recurrence and treatment failure still observed for most cancer subtypes and the
ASU Biodesign Institute spinout, OncoMyx Therapeutics, and Skysong Innovations complete licensing agreement
OncoMyx Therapeutics, an Arizona State University (ASU) spinout and privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform, has finalized a licensing agreement with Skysong Innovations, ASU's technology transfer organization.